Metropolitan Life Insurance CO Ikena Oncology, Inc. Transaction History

Metropolitan Life Insurance CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$3.5 - $7.31 $4,396 - $9,181	1,256 New	1,256 $8,000
Q1 2022 May 12, 2022	SELL	$5.61 - $13.85 $48,795 - $120,467	-8,698 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$10.52 - $16.96 $91,502 - $147,518	8,698 New	8,698 $109,000
Q4 2021 Mar 30, 2023	BUY	$10.52 - $16.96 $91,502 - $147,518	8,698 New	8,698 $109,000
Q4 2021 Feb 15, 2022	BUY	$10.52 - $16.96 $91,502 - $147,518	8,698 New	8,698 $109,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $56.9M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.